Calif. voters lean toward stem cell measure-pol
By Reuters,
Reuters
| 09. 24. 2004
LOS ANGELES, Sept 23 (Reuters) - A majority of likely voters in California favor a ballot proposal that would authorize $3 billion in state bonds to fund controversial stem cell research, according to a poll released on Thursday.
The referendum, on the Nov. 2 ballot, would create the largest pool of public funding for such research in the United States at a time when the Bush administration has sharply curtailed spending on studies involving embryonic stem cells.
Backers of the initiative, including Hollywood celebrities and Silicon Valley billionaires, argue that such research could potentially lead to cures for diseases such as Parkinson's, Alzheimer's and diabetes.
A survey by the Los Angeles Times showed that while most voters had not yet formed an opinion on the ballot measure known as Proposition 71, a majority expressed support once they were read the proposal itself.
The survey showed 54 percent of likely voters in California said they were inclined to vote for the stem cell proposal, compared with 32 percent who said they would vote against it.
Fourteen percent said they were not...
Related Articles
By Priyanka Runwal, Chemical and Engineering News | 08.05.2024
Saritee Sanodiya, 26, has spent countless days wondering if she’ll ever live a “normal” life. Growing up, Sanodiya often missed school, frequenting the hospital for sudden, life-threatening drops in her hemoglobin levels and excruciating pain in her joints. High fever...
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
By Sarah Kliff and Azeen Ghorayshi, The New York Times | 07.15.2024